ArticleEuropean journal of pain (London, England)2026
Effects of Tetrodotoxin on Safety, and Sensory and Respiratory Systems: A Dose-Escalating Study in Healthy Volunteers.
Article in European journal of pain (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic pain affects approximately 1.5 billion individuals worldwide, and currently available treatments often fail to provide adequate analgesia. Consequently, there is a need to explore novel analgesic compounds, including tetrodotoxin. In this study, we evaluated sensory and respiratory biomarkers of tetrodotoxin exposure in healthy volunteers.
methodsTwenty-five healthy participants (mean age 23 years) were enrolled in a single-blind, dose escalation study conducted over two days. Participants received subcutaneous injections of tetrodotoxin at doses of 30 μg and 45 μg. Changes from baseline to 1 h post administration were assessed using quantitative sensory testing, olfactory function testing, hypoxic ventilatory response measurements and standardised neurological examinations.
resultsAdministration of 30 μg tetrodotoxin resulted in significant alterations in mechanical detection threshold, pressure pain threshold and electrical pain tolerance. At the 45 μg dose, a modest effect on the cold pressor test was observed. No significant changes were detected in hypoxic ventilatory response or olfactory function at either dose. Tetrodotoxin was well tolerated, and no serious adverse events were reported.
conclusionsThese findings suggest that subcutaneous tetrodotoxin at doses of 30 μg and 45 μg produces modest effects on specific sensory parameters in healthy individuals and demonstrates a favourable short-term safety profile. SIGNIFICANCE STATEMENT: This study provides the first comprehensive assessment of tetrodotoxin's effects on sensory and respiratory function in healthy humans. It shows that 30 μg and 45 μg doses selectively modulate mechanical detection and pressure pain thresholds without affecting olfaction, neurological performance or hypoxic ventilatory response. These findings confirm the short-term safety of tetrodotoxin and advance understanding of its human pharmacodynamics, supporting its continued evaluation as a potential analgesic for chronic or neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.